{"name": "NephroGenex",
 "permalink": "nephrogenex",
 "crunchbase_url": "http://www.crunchbase.com/company/nephrogenex",
 "homepage_url": "http://www.nephrogenex.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "609-986-1780",
 "description": "",
 "created_at": "Thu Mar 18 04:06:25 UTC 2010",
 "updated_at": "Thu Mar 18 04:15:21 UTC 2010",
 "overview": "\u003Cp\u003ENephroGenex is a drug-development company focusing on kidney disease. The Company is developing Pyridorin\u00e2\u201e\u00a2 (pyridoxamine dihydrochloride) as a treatment to slow the progression of diabetic kidney disease.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       28],
      "assets/images/resized/0008/0755/80755v1-max-150x150.jpg"],
     [[250,
       47],
      "assets/images/resized/0008/0755/80755v1-max-250x250.jpg"],
     [[300,
       57],
      "assets/images/resized/0008/0755/80755v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$3.3M",
 "funding_rounds":
  [{"round_code": "a",
    "source_url": "http://localtechwire.com/business/local_tech_wire/venture/story/1565702/",
    "source_description": "NephroGenex Closes on $3.3M in New Financing",
    "raised_amount": 3300000.0,
    "raised_currency_code": "USD",
    "funded_year": 2007,
    "funded_month": 7,
    "funded_day": 6,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Care Capital",
         "permalink": "care-capital",
         "image":
          {"available_sizes":
            [[[110,
               80],
              "assets/images/resized/0004/9581/49581v1-max-150x150.jpg"],
             [[110,
               80],
              "assets/images/resized/0004/9581/49581v1-max-250x250.jpg"],
             [[110,
               80],
              "assets/images/resized/0004/9581/49581v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company":
        {"name": "BioStratum",
         "permalink": "biostratum",
         "image": null},
       "financial_org": null,
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Vanderbilt University Office of Investments",
         "permalink": "vanderbilt-university-office-of-investments",
         "image":
          {"available_sizes":
            [[[150,
               22],
              "assets/images/resized/0004/6379/46379v1-max-150x150.jpg"],
             [[250,
               37],
              "assets/images/resized/0004/6379/46379v1-max-250x250.jpg"],
             [[440,
               66],
              "assets/images/resized/0004/6379/46379v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "104 Carnegie Center, Suite 214",
    "address2": "",
    "zip_code": "08540",
    "city": "Princeton",
    "state_code": "NJ",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [{"available_sizes":
     [[[150,
        90],
       "assets/images/resized/0008/0756/80756v1-max-150x150.jpg"],
      [[250,
        150],
       "assets/images/resized/0008/0756/80756v1-max-250x250.jpg"],
      [[450,
        270],
       "assets/images/resized/0008/0756/80756v1-max-450x450.jpg"]],
    "attribution": null}],
 "external_links":
  []}